The third will be
A third coronavirus vaccine has been registered in Russia
Polina Loseva, N+1
An inactivated coronavirus vaccine from the Chumakov Center, KoviVak, has been registered in Russia. This is the third in Russia has a vaccine that can now be used for mass vaccination.
The results of phase 1-2 of the KoviVak clinical trials have not yet been published, but the temporary registration of the vaccine suggests that the developers will report on the third phase of trials by the end of 2021.
Most of the coronavirus vaccines that are currently approved for widespread use in different countries have been created using new technologies that have not received such distribution before. Moderna and AstraZeneca Johnson & Johnson vaccines, as well as adenovirus vectors (Russian Sputnik, as well as vaccines from the companies AstraZeneca and Johnson & Johnson) and mRNA (Pfizer and Moderna vaccines).
At the same time, in several countries, classical approaches to the creation of vaccines are also used – based on weakened viruses or individual viral peptides. However, these developments are moving slower so far. While Sputnik has already reached the stage of mass vaccination, the peptide vaccine of the Vector center (EpiVacCorona) is still not widely used, although it was registered in the middle of autumn 2020. And inactivated vaccines lag even further behind – only at the end of autumn the world's first inactivated vaccine (from the Chinese company Sinovac) passed the initial phase of testing.
Now in Russia has registered the first inactivated coronavirus vaccine. It was created at the Scientific Center for Research and Development of Immunobiological Drugs named after Chumakov of the Russian Academy of Sciences. It was called "KoviVak". The vaccine consists of coronavirus particles that are grown inside cells, and then "killed" with beta-propiolactone and heating – so that the virus loses the ability to infect the cells of a vaccinated person. We talked in detail about how it was invented and created in the material "Dead Water".
Like its predecessors, Sputnik and EpiVacCorone, the KoviVac vaccine was registered even before the publication of the results of clinical trials. The report on the first phases of the Sputnik trials appeared after registration, the report on the third phase – after the start of mass vaccination. The results of the EpiVacCorona tests have not yet been published anywhere. Similarly, there is no information about the KoviVak tests, except that they began in the fall of 2020 and four hundred people took part in the 1-2 phase, according to the Ministry of Science and Higher Education of the Russian Federation. However, in all three cases, this registration is temporary. At KoviVak, it is valid only until 2022 – during this time, developers must submit test data and receive final registration.
The third phase, according to the press service of the ministry, is scheduled for March 2021, three thousand people will take part in it. At the same time, the Minister of Science and Higher Education Valery Falkov promised to start mass vaccination with the use of "KoviVak" in the same spring. This means, as in the case of Sputnik, vaccination will begin simultaneously with post-registration clinical trials.
According to the instructions for use, "KoviVak" must be stored at a temperature of 2-8 degrees and cannot be frozen. It is designed for two injections with an interval of two weeks and is intended for people from 18 to 60 years old. To expand these age limits, developers need to conduct separate tests on children and the elderly. About side effects in the instructions it is reported that very often (from 10 to 15 percent of cases) there is pain at the injection site, in 1-2 percent of cases – headache and fever.
Portal "Eternal youth" http://vechnayamolodost.ru